SecBot SecBot
8-K ·Filed Sep 10, 2026

LH

LABCORP HOLDINGS INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed2mo ago SEC0000920148-26-000201
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The long-term outlook (5-8% revenue CAGR, 8.5-11.5% EPS CAGR) is in line with the company's historical performance and provides a clear framework for valuation. Monitor upcoming quarterly results for execution against the 2026 guidance and any updates on M&A pipeline or LaunchPad savings. The stock has outperformed the S&P 500 Healthcare index since the prior Investor Day (144% vs 88% TSR), suggesting elevated expectations are already priced in.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$311.54
T+0 close · Sep 10, 2026 · via day close
Latest settled
+0.20%
T+20 · $312.15 · next T+60 in 20d
Vs SPY
−1.67%
α at T+20
Latest observation
+20.49%
T+44 · FF3 residual α
  1. T+0 · Sep 11 $311.54entry
  2. T+1 · 2mo ago +1.21%α +1.66% · $315.31
  3. T+5 · 2mo ago +2.94%α +3.16% · $320.71
  4. T+20 · 6w ago +0.20%α −1.67% · $312.15
  5. T+46 · todayOpen
  6. T+60 · in 20d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Labcorp held its 2026 Investor Day, reaffirming full-year 2026 guidance and providing a long-term outlook through 2029. The company targets 5%-8% compound annual revenue growth and 8.5%-11.5% adjusted EPS CAGR, driven by specialty diagnostics, technology, and M&A. The filing is a routine strategic update with no new financial data beyond previously issued guidance.

Key Facts

  • Reaffirmed FY2026 guidance: Enterprise revenue $14.71B-$14.83B (+5.4% to +6.3% YoY), Adjusted EPS $18.10-$18.55 (+10.1% to +12.8% YoY), Free Cash Flow $1.24B-$1.36B.
  • Long-term outlook (2026-2029): 5%-8% revenue CAGR, 75-150 bps adjusted operating margin expansion by end of 2029, 8.5%-11.5% adjusted EPS CAGR.
  • Organic revenue growth target of 3.5%-5.5% CAGR, with M&A contributing an additional 1.5%-2.5% CAGR.
  • Diagnostics segment revenue grew from $9.4B in 2023 to $11.5B at 2026 guidance midpoint (7% CAGR).
  • Biopharma Laboratory Services revenue grew from $2.8B in 2023 to $3.3B at 2026 guidance midpoint (6% CAGR).
  • Capital deployment from 2023-2025: $6.1B total, with $3.7B reinvested in the business ($1.4B CapEx, $2.3B M&A) and $2.4B returned to shareholders ($0.7B dividends, $1.7B share repurchases).
  • LaunchPad productivity savings targeted at $125M-$150M per year.
  • Financial leverage target: 2.5x to 3.0x gross debt to TTM adjusted EBITDA.
  • Specialty diagnostics (oncology, neurology, autoimmune, women's health) generating $2B in annual revenue with strong growth rates.
  • Over 30 M&A deals from 2023-2025 contributed $900M in acquired revenue.

Financial Impact

Reaffirmed FY2026 guidance: Enterprise revenue $14.71B-$14.83B, Adjusted EPS $18.10-$18.55, Free Cash Flow $1.24B-$1.36B. Long-term targets: 5%-8% revenue CAGR, 8.5%-11.5% adjusted EPS CAGR through 2029.

revenueepsfree cash flowoperating margin

Risk Factors

  • Potential impact of PAMA (Protecting Access to Medicare Act) on diagnostics reimbursement.
  • Foreign exchange headwinds (0.4% impact on enterprise revenue, 1.5% on BLS).
  • Execution risk on M&A integration and achieving targeted 1.5%-2.5% acquisition revenue CAGR.
  • Macroeconomic pressures and inflation affecting healthcare utilization.
  • Competition from hospital labs and other independent lab providers.

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories
Analyst Consensus
78% bullish (27 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000920148-26-000201
Document: formpr091026ex991investord.htm0000920148-26-000201
Document: lh-20260910.htm0000920148-26-000201
Document: 0000920148-26-000201-index-headers.html0000920148-26-000201
Document: 0000920148-26-000201-index.html0000920148-26-000201
Document: 0000920148-26-000201.txt0000920148-26-000201

Track record

29 reports on LH

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.60% at T+60 after the Apr 30, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $372.32 Now $372.46 +0.04% settles Nov 19
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
  3. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
  4. Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
  6. Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
  7. Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
  8. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
  9. Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
  10. Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026